Endocrinology
Conference Coverage
EMPEROR-Preserved findings confirmed in ‘true’ HFpEF patients
From the Journals
Nondiabetes hospitalization is wrong time to up diabetes meds
Diabetes treatment intensification after being hospitalized for reasons other than diabetes was linked with a short-term increase in risk of...
From the Journals
Expensive insulins, pen devices dominate U.S. diabetes care
Analog insulins continue to represent more than 80% of prescriptions for type 2 diabetes in the U.S., despite rising costs and public scrutiny of...
From the Journals
Synthetic chemical in consumer products linked to early death, study says
Daily exposure to phthalates may lead to hundreds of thousands of early deaths each year among older adults in the United States.
Conference Coverage
Adding statins to steroids in thyroid eye disease improves outcomes
The drugs were linked to improvements in Graves’ orbitopathy, even in people without high LDL-cholesterol.
From the Journals
Statins tied to diabetes progression
A real-world study reaffirms the link shown in clinical trials, but the message remains: “No patient should stop taking their statins based on our...
Conference Coverage
EMPEROR-Preserved: Empagliflozin’s HFpEF efficacy catalyzes a heart failure redefinition
Cardiologists have long defined heart failure as involving reduced or preserved ejection fraction. Results from big empagliflozin trials say...
Conference Coverage
EMPEROR-Preserved spouts torrent of reports on empagliflozin treatment of HFpEF
The primary report from EMPEROR-Preserved on using empagliflozin to treat patients with HFpEF arrived with four other analyses published in its...
From the Journals
Walnuts lowered LDL cholesterol in healthy seniors: WAHA study
A large study of healthy elderly people found that regular consumption of walnuts may lower a number of lipid biomarkers, including LDL...
Conference Coverage
Dapagliflozin in HFrEF may cut arrhythmias, sudden death: DAPA-HF
Response to the positive findings was tempered, however, by the post hoc nature of the analysis, choice of primary outcome, and inconsistencies...
Conference Coverage
EMPEROR-Preserved: Empagliflozin scores HFpEF breakthrough
Empagliflozin is the first treatment to produce an unequivocal, hard-endpoint benefit in patients with heart failure with preserved ejection...